Cortexyme rebrands as Quince Therapeutics, shifts to bone-targeting drugs, reports $105M cash

Quince Therapeutics, Inc.

Cash, cash equivalents and short-term investments: ~$105M as of June 30, 2022 (preliminary).
Name changed from Cortexyme to Quince Therapeutics; ticker changes from CRTX to QNCX effective Aug 1, 2022.
Strategic focus on bone-targeting drug platform and lead molecule NOV004; Phase 1 clinical studies expected in 2023.
Plans to in-license or acquire clinical-stage assets for debilitating/rare diseases and out-license legacy neuroscience assets.
Cash runway expected to fund operations into second half of 2025; corporate restructuring completed in H1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.